A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events observed at the IDE397 30mg and ...
Researchers have discovered that the combination of the two cancer drugs Rapamycin and Trametinib significantly extends the lifespan of mice. This therapy shows greater effects than the individual ...
Rapid, combined and personalized non-invasive stimulation of the precuneus improves associative memory, enhances local gamma expression, and strengthens precuneus–hippocampal connectivity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback